Medicis, Mylan Settle Suits Over Acne Drug

Law360, New York (July 23, 2010, 5:14 PM EDT) -- Medicis Pharmaceutical Corp. has worked out a deal that resolves litigation stemming from Mylan Inc.’s launch of a generic version of acne treatment Solodyn and its plans to sell Medicis’ drug in new dosage levels.

Scottsdale, Ariz.-based Medicis on Thursday entered into a settlement and license agreement with Mylan and its affiliates Matrix Laboratories Ltd. and Mylan Pharmaceuticals Inc. that brings an end to Medicis’ two patent infringement cases over Solodyn extended-release tablets.

Mylan confirmed that Medicis’ patent for the drug is valid and enforceable, and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.